Press Releases
Developers of complex molecules must prioritize both the efficacy and developability of intricate biologics—for instance, bispecific antibodies.
Maintaining these critical characteristics of a bsAb requires versatile platforms and technologies, but more importantly, experts experienced in leveraging these advanced tools to advance difficult-to-express molecules to the next level.
Our bsAb experts—Jina Kim and Haejin Kweon—discuss their cumulative industry knowhow of how a bsAb molecule can be developed in full without compromising quality.
Developers of complex molecules must prioritize both the efficacy and developability of intricate biologics—for instance, bispecific antibodies.
Maintaining these critical characteristics of a bsAb requires versatile platforms and technologies, but more importantly, experts experienced in leveraging these advanced tools to advance difficult-to-express molecules to the next level.
Our bsAb experts—Jina Kim and Haejin Kweon—discuss their cumulative industry knowhow of how a bsAb molecule can be developed in full without compromising quality.